Procalcitonin: A marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 3, 2009, Pages 861-868

  Alicia Algeciras Schimnich, ^a   Carol M Preissner, ^a   J Paul Theobald, ^a   Mary S Finseth, ^a   Stefan, K Grebe ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; PROCALCITONIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CALCITONIN BLOOD LEVEL; CANCER PATIENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MASTOCYTOSIS; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; THYROID CARCINOMA; THYROID DISEASE; THYROID FOLLICLE CELL; THYROID MEDULLARY CARCINOMA;

EID: 62349091697     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1862     Document Type: Article

References (21)

1. Giuffrida D, Gharib H 1998 Current diagnosis and management of medullary thyroid carcinoma. Ann Oncol 9:695-701
2. Laure Giraudet A, Al Ghulzan A, Auperin A, Leboulleux S, Chehboun A, Troalen F, Dromain C, Lumbroso J, Baudin E, Schlumberger M 2008 Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 158:239-246
3. Saad MF, Fritsche HA, Jr., Samaan NA 1984 Diagnostic and prognostic values of carcinoembryonic antigen in medullary carcinoma of the thyroid. J Clin Endocrinol Metab 58:889-894
4. Leboulleux S, Baudin E, Travagli JP, Schlumberger M 2004 Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 61:299-310
5. Niccoli P, Conte-Devolx B, Lejeune PJ, Carayon P, Henry JF, Roux F, Wion-Barbot N, Bigorgne JC 1996 [Hypercalcitoninemia in conditions other than medullary cancers of the thyroid ]. Ann Endocrinol (Paris) 57:15-21
6. Iacobone M, Niccoli-Sire P, Sebag F, De Micco C, Henry JF 2002 Can sporadic medullary thyroid carcinoma be biochemically predicted ? Prospective analysis of 66 operated patients with elevated serum calcitonin levels. World J Surg 26:886-890
7. Silva OL, Broder LE, Doppman JL, Snider RH, Moore CF, Cohen MH, Becker KL 1979 Calcitonin as a marker for bronchogenic cancer: a prospective study. Cancer 44:680-684
8. Zaidi M, Moonga BS, Bevis PJ, Bascal ZA, Breimer LH 1990 The calcitonin gene peptides: biology and clinical relevance. Crit Rev Clin Lab Sci 28:109-174
9. Fugazzola L, Pinchera A, Luchetti F, Iacconi P, Miccoli P, Romei C, Puccini M, Pacini F 1994 Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma. Int J Biol Markers 9:21-24
10. Becker KL, Snider RH, Silva OL, Moore CF 1978 Calcitonin heterogeneity in lung cancer and medullary thyroid cancer. Acta Endocrinol 89:89-99
11. Goltzman D, Tischler AS 1978 Characterization of the immunochemical forms of calcitonin released by a medullary thyroid carcinoma in tissue culture. J Clin Invest 61:449-458
12. Austin LA, Heath 3rd H 1981 Calcitonin: physiology and pathophysiology. N Engl J Med 304:269-278
13. Meisner M, Schmidt J, Huttner H, Tschaikowsky K 2000 The natural elimination rate of procalcitonin in patients with normal and impaired renal function. Intensive Care Med 26(Suppl 2):S212-S216
14. Meisner M, Tschaikowsky K, Schnabel S, Schmidt J, Katalinic A, Schuttler J 1997 Procalcitonin-influence of temperature, storage, anticoagulation and arterial or venous asservation of blood samples on procalcitonin concentrations. Eur J Clin Chem Clin Biochem 35:597-601
15. Schneider HG, Lam QT 2007 Procalcitonin for the clinical laboratory: a review. Pathology 39:383-390
16. Bihan H, Becker KL, Snider RH, Nylen E, Vittaz L, Lauret C, Modigliani E, Moretti JL, Cohen R 2003 Calcitonin precursor levels in human medullary thyroid carcinoma. Thyroid 13:819-822
17. Ghillani PP, Motte P, Troalen F, Jullienne A, Gardet P, Le Chevalier T, Rougier P, Schlumberger M, Bohuon C, Bellet D 19 89 Identification and measurement of calcitonin precursors in serum of patients with malignant diseases. Cancer Res 49:6845-6851
18. 2008 Defining, establishing, and verifying reference intervals in the clinical laboratory, Approved Guideline, third edition. Clinical and Laboratory Science Institute (CLSI), Wayne, PA, Doccument C28-A3
19. Matzaraki V, Alexandraki KI, Venetsanou K, Piperi C, Myrianthefs P, Malamos N, Giannakakis T, Karatzas S, Diamanti-Kandarakis E, Baltopoulos G 2007 Evaluation of serum procalcitonin and interleukin-6 levels as markers of liver metastasis. Clin Biochem 40:336-342
20. Martinetti A, Seregni E, Ferrari L, Pallotti F, Aliberti G, Coliva A, Fracassi S, Bombardieri E 2003 Evaluation of circulating calcitonin: analytical aspects. Tumori 89:566-568
21. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, LiVosli VA, Niccoli-Sire P, John R, Ruf J, Smyth PP, Spencer CA, Stockigt JR 2003 Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 13:3-126